Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc. (NASDAQ:NVAX ) Baird 2022 Global Healthcare Conference Call September 13, 2022 8:30 AM ET Company Participants Gregory Glenn - President, R&D John Trizzino - Chief Commercial Officer and Chief Business Officer Unidentified Analyst Hey, good morning, everyone and welcome to Baird's Annual Healthcare Conference. I am really pleased to be kicking off the conference with Novavax.

Novavax, Inc. (NVAX) Baird 2022 Global Healthcare Conference Transcript

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

GAITHERSBURG, Md. , Sept. 13, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases and Serum Institute of India Pvt.

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older

Novavax, Inc. (NASDAQ:NVAX ) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 4:00 PM ET Company Participants Gregory Glenn - Chief Scientific Officer John Trizzino - Chief Business Officer and Chief Commercial Officer Conference Call Participants Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)

Shares of Novavax Inc. NVAX, +1.83% were up 2.4% in trading on Monday after the company said its COVID-19 booster has been authorized in Europe for adults. Novavax's stock has declined 77.3% so far this year, while the S&P 500 SPX, +1.27% is down 14.6%.

Novavax's COVID-19 booster is now authorized in Europe

Nuvaxovid™ is now authorized in the EU for use in adults aged 18 and older as a booster regardless of previous vaccine history GAITHERSBURG, Md. , Sept. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older

Heron Therapeutics

Mirati Therapeutics

Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.

3 Stocks Expecting Good News From the FDA

Moderna

Pfizer

Pfizer, Moderna, and Novavax all had a rough month in August.

Here's Why These Top 3 COVID-19 Vaccine Stocks Broke Down in August

Bumble

Tandem Diabetes Care

Nasdaq Bear Market: 3 Growth Stocks That Crashed Over 30% in August

Affirm

Aurora Innovation

Coinbase

GoodRx Holdings

Kornit Digital

Matterport

TuSimple Holdings

10X Genomics

Upstart Holdings

The best performer on this list has lost three-fourths of its value this year.

Should You Buy the Nasdaq's 10 Worst-Performing 2022 Stocks?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Novavax (NVAX) Down 29.2% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

The vaccine maker's recent regulatory victories aren't landing with investors.

Why Novavax Stock Sank to a New 52-Week Low Today

Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.

Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland

The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.

Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation

GAITHERSBURG, Md. , Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in Switzerland for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17 and as a heterologous and homologous booster dose for adults aged 18 and older.

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

GlaxoSmithKline

Merck

Morgan Stanley

Novartis

Sanofi

It started out relatively small, or as small as a recall of one of the first drugs to top $1 billion in annual sales can be. In September 2019, individual companies began recalling popular heartburn medication Zantac.

This Overlooked Danger Could Tank Big Pharma Stocks

Authorization could allow Nuvaxovid™ to be used as a booster regardless of previous vaccine history GAITHERSBURG, Md. , Sept. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older.

Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

The coronavirus' decline is continuing; meanwhile, rival vaccine developers are still moving ahead.

Why Novavax Stock Got Pummeled Today

It's been a horrendous stretch for Novavax (NASDAQ: NVAX ) stock, and it's not getting any better on Wednesday. Shares of NVAX stock are down 6.5% today.

Why Is Novavax (NVAX) Stock Down Today?

Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.

Is Novavax A Sell After Its Quarterly Flop Led To A Guidance Cut?

AMC Entertainment

Carvana

DraftKings

GameStop

Lucid Group

Marathon Digital Holdings

Roundhill Meme ETF

Invitae

Tilray Brands

If you think investing in "meme stocks" is like playing a game of musical chairs, you might be surprised at how quickly the music might stop. The post 9 Key Meme Stocks To Run Out Of Money In Less Than 2 Years appeared first on Investor's Business Daily.

9 Key Meme Stocks To Run Out Of Money In Less Than 2 Years

BioNTech SE

They still might offer solid long-term opportunities for investors.

After Double-Digit Percentage Declines, Are Vaccine Stocks Buys?

Nuvaxovid™ will be the first protein-based vaccine available for adolescents aged 12 through 17 in the United Kingdom GAITHERSBURG, Md. , Aug. 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine▼ for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

The superior reactogenicity profile of Novavax's Nuvaxovid vaccine could make it the preferred choice amongst some in an endemic COVID environment. The company's other promising vaccine, NanoFlu, is being overlooked due to the market's focus on COVID.

News for Novavax Stock (NVAX)